论文部分内容阅读
应用红细胞Ｃ３ｂ受体花环（ＲＢＣ－Ｃ３ｂＲ）及红细胞免疫复合物花环（ＲＢＣ－ＩＣＲ）和巨噬细胞吞噬功能等技术，对５２例正常人和６０例恶性肿瘤患者（胃癌，肺癌，骨肿瘤，食管癌，肝癌）进行检测。结果显示，恶性肿瘤患者ＲＢＣ－Ｃ３ｂＲ值（１１．００％±３．４９％，ｘ±ｓ）、巨噬细胞吞噬百分率（ＰＲ％，４２．１７％±４．６４％）、吞噬指数（ＰＩ０．６３±０．１４）明显低于正常人（ＲＢＣ－Ｃ３ｂＲ２１．３８％±２．５９％，ＰＲ，６２．５０％±４．００％，ＰＩ，１．３０±０．０５），而ＲＢＣ－ＩＣＲ值（２４．０７％±４．１６％），明显高于正常人（９．００±１．６０），经统计学方法（均数、标准差和ｔ检验）处理，均相差非常显著（Ｐ＜０．０１）。恶性肿瘤患者指标变化与其相应红细胞和白细胞数不相关。这些结果说明，恶性肿瘤患者由于病情的发展和恶病质的发生，对其机体免疫功能损害比较严重，导致免疫功能低下。这些指标的变化，为临床提示恶性肿瘤患者在抗肿瘤治疗的同时，免疫治疗应占重要的位置
Using red blood cell C3b receptor rosette (RBC-C3bR) and red blood cell immune complex rosette (RBC-ICR) and macrophage phagocytosis and other technologies, 52 cases of normal and 60 cases of cancer patients (gastric cancer, lung cancer, bone tumor, Esophageal cancer, liver cancer) were tested. The results showed that RBC-C3bR values (11.00%±3.49%, x±s), macrophage phagocytosis (PR%, 42.17%±4.64%), and phagocytic index (PI0) in patients with malignant tumors. .63±0.14) was significantly lower than normal (RBC-C3bR21.38%±2.59%, PR, 62.50%±4.00%, PI, 1.30±0.05), and RBC -ICR value (24.07%±4.16%) was significantly higher than normal (9.00±1.60). Statistical methods (mean, standard deviation, and t-test) showed significant difference (P<0.01). The change in the index of patients with malignant tumors was not related to the corresponding number of red blood cells and white blood cells. These results show that patients with malignant tumors have severely compromised their immune function due to the development of their disease and the development of cachexia, leading to low immune function. The changes of these indicators are clinically suggestive of cancer patients in the anti-tumor therapy, while immunotherapy should occupy an important position